Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 567-578

  Zhang, Minli ^a   Zhou, Diansong ^a   Wang, Yi ^a   Maier, Donna L ^a   Widzowski, Daniel V ^a   Sobotka Briner, Cynthia D ^a   Brockel, Becky J ^a   Potts, William M ^a   Shenvi, Ashok B ^a   Bernstein, Peter R ^a   Pierson, M Edward ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 8 (4 METHYLPIPERAZIN 1YL) N (4 MORPHOLIN 4 YLPHENYL)CHROMANE 2 CARBOXAMIDE; AZD 3783; PLACEBO; SEROTONIN 1B ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BODY TEMPERATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; GUINEA PIG; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; MATERNAL DEPRIVATION; MAXIMUM PLASMA CONCENTRATION; MEDIAN EFFECTIVE CONCENTRATION; MICROSOME; NEUROPHARMACOLOGY; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE DRUG DOSE; STEADY STATE; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BENZOPYRANS; DISEASE MODELS, ANIMAL; DOGS; DOUBLE-BLIND METHOD; GUINEA PIGS; HEPATOCYTES; HUMANS; HYPOTHERMIA, INDUCED; MACACA FASCICULARIS; MALE; MICROSOMES, LIVER; MOLECULAR TARGETED THERAPY; MORPHOLINES; P-GLYCOPROTEINS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79952488254     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174433     Document Type: Article

References (39)

1. Ahlgren C, Eriksson A, Tellefors P, Ross SB, Stenfors C, and Malmberg A (2004) In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine 1B autoreceptor antagonist. Eur J Pharmacol 499:67-75. (Pubitemid 39201212)
2. Byrne SE and Rothschild AJ (1998) Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 59:279-288. (Pubitemid 28353975)
3. Chiou WL, Jeong HY, Chung SM, and Wu TC (2000) Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135-140. (Pubitemid 30158360)
4. Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, Arban R, Poffe A, Melotto S, Hagan JJ, et al. (2006) Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin- 1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1, 2,4- oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology 50:975-983. (Pubitemid 44208836)
5. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, and Heninger GR (1990) Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-418. (Pubitemid 20161259)
6. Dressman JB (1986) Comparison of canine and human gastrointestinal physiology. Pharm Res 3:123-131.
7. Fink KB and Göthert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360-417.
8. Gaster LM, Ham P, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Price GW, Roberts C, Routledge C, et al. (1998) The selective 5-HT1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. Ann NY Acad Sci 861:270-271. (Pubitemid 29047745)
9. Goldstein BJ and Goodnick PJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders. III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12(3 Suppl B):S55-S87. (Pubitemid 28556670)
10. Grimwood S and Hartig PR (2009) Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther 122:281-301.
11. Hagan JJ, Slade PD, Gaster L, Jeffrey P, Hatcher JP, and Middlemiss DN (1997) Stimulation of 5 HT1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol 331:169-174. (Pubitemid 27331446)
12. Hetrick SE, McKenzie JE, and Merry SN (2010) The use of SSRIs in children and adolescents. Curr Opin Psychiatry 23:53-57.
13. Hillegaart V and Ahlenius S (1998) Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181. Br J Pharmacol 125:1733-1743. (Pubitemid 29000820)
14. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
15. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
16. Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Ryan C, Ross S, and Stenfors C (2003) Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine 1B antagonist. J Pharmacol Exp Ther 304:1072-1084. (Pubitemid 36254420)
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
18. Keane PE and Soubrié P (1997) Animal models of integrated serotoninergic functions: their predictive value for the clinical applicability of drugs interfering with serotoninergic transmission, in Handbook of Experimental Pharmacology: Serotoninergic Neurons and 5-HT Receptors in the CNS (Baumgarten HG, Göthert M, eds) pp 707-725, Springer, Berlin.
19. 3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther 330:342-351.
20. Maj J, Chojnacka-Wójcik E, Kłodzińska A, Dereń A, and Moryl E (1988) Hypothermia induced by m- trifluoromethylpiperazine or m-chlorophynylpiperazine: an effect mediated by 5-HT1B receptors? J Neural Transm 73:43-55.
21. Mendlewicz J and Lecrubier Y (2000) Antidepressant selection: proceedings from a TCA/SSRI Consensus Conference. Acta Psychiatr Scand Suppl 403:5-8.
22. Möller HJ and Volz HP (1996) Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 52:625-638.
23. 1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404:1-12.
24. 11C]P943. Nucl Med Biol 37:205-214.
25. Nutt DJ (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69(Suppl E1):4-7.
26. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
27. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
28. Oie S and Tozer TN (1979) Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68:1203-1205. (Pubitemid 10231273)
29. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnäs K, Takano A, Karlsson P, Gulyás B, Medd AM, et al. (2008) [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 41:1075-1085.
30. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
31. Roberts C, Price GW, and Middlemiss DN (2001) Ligands for the investigation of 5-HT autoreceptor function. Brain Res Bull 56:463-469. (Pubitemid 34031781)
32. 1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr Top Med Chem 2:559-574.
33. 1B receptor antagonist, AR-A000002. Naunyn Schmiedebergs Arch Pharmacol 369:330-337.
34. Sussman N (2008) Medical complications of SSRI and SNRI treatment. Primary Psychiatry 15:37-41.
35. Tsai S-J and Hong C-J (2003) Pharmacogenetics of selective serotonin reuptake inhibitor response in major depression. Curr Pharmacogenomics 1:1-7.
36. 11C]AZ10419369. Psychopharmacology 213:533-545.
37. Watson JM, Burton MJ, Price GW, Jones BJ, and Middlemiss DN (1996) GR127935 acts as a partial agonist at recombinant human 5-HT1Dα and 5-HT1Dβ receptors. Eur J Pharmacol 314:365-372. (Pubitemid 26382442)
38. Zgombick JM, Bard JA, Kucharewicz SA, Urquhart DA, Weinshank RL, and Branchek TA (1997) Molecular cloning and pharmacological characterization of guinea pig 5-HT1B and 5-HT1D receptors. Neuropharmacology 36:513-524. (Pubitemid 27272097)
39. Zhou D, Zhang M, Otmani SA, Shen C, Wang Y, and Grimm SW (2008) In vitro metabolism of AZ12320927: metabolite profiling in human, rat, dog, guinea pig, mouse and rabbit hepatocytes and enzymes identification in human liver microsomes. Drug Metab Rev 3:147.